KMT2A and leukemia: To examine the selectivity of SGF29 inhibition against different blood cancer types, we performed Cpd_DC60 titration experiments in MLL-r leukemia (Fig. 6A, red; seven cell lines), non–MLL-r blood cancer (green; seven cell lines), and solid tumor (blue; three cell lines) cells.